EGFR and non-small cell lung carcinoma: Our study similarly found that EGFR‐mutated NSCLC patients with BoM experience shorter PFS (10.5 vs. 12.6 months, p = 0.002, Figure 2A) and OS (30.9 vs. 49.7 months, p < 0.001) compared to those without.